Placeholder

Biotech: Raising Capital in a Tight Market

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 2163. Categories: , .

Product Description

The global financial crisis has made it challenging for the biotechnology industry to raise capital to fund innovation. Experts say venture capital money is still available, but often the VC community is looking for lower-risk, short-term projects.
As a result, biotech companies are increasingly looking to alternative sources of capital. Experts say this is a natural reaction to normal business cycles, and when venture funding dries up companies embark on other…

Sidebars:
Tips for Attracting Funding
Recession’s Impact on Biotech

Experts
William Baird III. Chief ­Financial Officer, PTC ­Therapeutics Inc., a biopharmaceutical company focused on the discovery, development, and ­commercialization of orally administered small-molecule drugs. For more information, visit ptcbio.com.
Gil Bashe. Executive VP, Makovsky & Company, a global public relations, investor ­relations, and branding consultancy. For more information, visit makovsky.com.
Oliver Fetzer, Ph.D. President and CEO, Cerulean Pharma Inc., a ­clinical-stage biopharmaceutical ­company specializing in the design and development of nanopharmaceuticals. For more ­information, visit ceruleanrx.com.
Glen Giovannetti. Global ­Biotechnology Leader, Ernst & Young, a ­global provider of assurance, tax, transaction, and advisory services. For more information, visit ey.com.
Matthew Hudes. National Managing Principal, Biotechnology, Deloitte ­Consulting LLP’s Life Sciences & Health Care Group, a management consulting firm. For more information, visit deloitte.com.
David Millard. Chair, Business Department, Barnes & Thornburg, a law firm. For more information, visit btlaw.com.
David Peralta. VP, Chief Operating ­Officer, and Chief Financial Officer, NanoBio Corp., a privately held biopharmaceutical company focused on developing and ­commercializing dermatological products, anti-infective treatments, and intranasal vaccines. For more information, visit nanobio.com.
Kevin Starr. Managing Partner, Third Rock Ventures, a venture capital firm focused on the life sciences. For more ­information, visit thirdrockventures.com.
Michael Weingarten. Director, The National Cancer Institute’s SBIR program, which provides grants and contract
funding opportunities to promising small businesses developing treatments for cancer. For more information, visit sbir.cancer.gov.

FEEDBACK